Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma

• Verfasst von: Ugurel, Selma [VerfasserIn]
• Verfasst von: Sucker, Antje [VerfasserIn]
• Verfasst von: Rittgen, Werner [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Titel: Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma
• Verf.angabe: Selma Ugurel, Nellie Bell, Antje Sucker, Anette Zimpfer, Werner Rittgen and Dirk Schadendorf
• E-Jahr: 2005
• Jahr: 14 June 2005
• Umfang: 6 S.
• Fussnoten: Gesehen am 22.01.2021
• Titel Quelle: Enthalten in: International journal of cancer
• Ort Quelle: Bognor Regis : Wiley-Liss, 1966
• Jahr Quelle: 2005
• Band/Heft Quelle: 117(2005), 5, Seite 825-830
• ISSN Quelle: 1097-0215
• DOI: doi:10.1002/ijc.21073
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: melanoma
• Sach-SW: plasma
• Sach-SW: S100β
• Sach-SW: serum
• Sach-SW: tumor M2-PK
• Sach-SW: tumor marker
• K10plus-PPN: 1745296018

Abstract

Proliferating cells express the pyruvate kinase isoenzyme type M2 (M2-PK). This enzyme exists as an active tetramer and an inactive dimer. The dimeric form is predominantly found in tumor cells and is therefore termed Tumor M2-PK (TuM2-PK). TuM2-PK molecules are released into the peripheral blood and may hereby function as a marker of tumor load in cancer patients. Our study was aimed to investigate TuM2-PK as a potential plasma marker in melanoma patients compared to the well-established serum marker S100β. We measured the concentration of TuM2-PK in plasma and S100β in corresponding serum samples from 300 melanoma patients and 53 healthy controls using a sandwich ELISA and an immunoluminometric assay, respectively. Plasma concentrations of TuM2-PK were significantly increased in melanoma patients compared to healthy controls (9.30 U/ml vs. 7.20 U/ml; p = 0.0036) and correlated with tumor load (p < 0.0005) and disease stage (p < 0.0005). Patients with elevated plasma TuM2-PK (cut-off = 15 U/ml) presented a reduced overall (p < 0.000005) and progression-free (p = 0.023) survival. Multivariate analysis revealed plasma TuM2-PK and serum S100β as independent predictors of overall survival in metastasized patients. Neither plasma TuM2-PK nor serum S100β showed prognostic relevance for tumor-free patients. Although the sensitivity and specificity to predict disease progression or death was higher for serum S100β compared to plasma TuM2-PK, the combination of both markers improved the estimation of prognosis compared to that of serum S100β alone.